# OnCo record paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021" ;
  schema:name "CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma"@en ;
  schema:description "A second PD-1 antibody, camrelizumab, also lengthened progression-free survival when added to gemcitabine and cisplatin in metastatic nasopharyngeal cancer, confirming that chemo-immunotherapy is the new first-line standard."@en ;
  schema:url <https://onco.cc/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(21)00302-8>, <https://pubmed.ncbi.nlm.nih.gov/34174189/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(21)00302-8> ;
  schema:datePublished "2021"^^xsd:gYear ;
  schema:author "Yang Y, Qu S, Li J, et al." ;
  onco:cancers <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/> ;
  onco:drugs <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/gemcitabine-cisplatin/> ;
  onco:trials <https://onco.cc/trials/captain-1st/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .